Shridhar Sanghvi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shridhar Sanghvi has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Harpreet Singh
Department of Physiology and Cell Biology, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA
6 shared publications - Devasena Ponnalagu
Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania
2 shared publications Andrew R. Kohut
Penn Heart and Vascular Center, University of Pennsylvania, Philadelphia, PA, USA
1 shared publicationDevasena Ponnalagu
Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, OH; Department of Pharmacology, The University of Washington, Seattle, WA
1 shared publication- Devendra Patel
Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, OH
1 shared publication - Diego Antelo
Department of Physiology and Cell Biology, The Ohio State University, Columbus, OH, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Canadian Science Publishing in Biochemistry and Cell Biology
- Vol. 103, 1-16
Zyxin directly binds to chromosomal DNA and is linked with mitochondrial integrity and apoptosis
Human zyxin is a key component of the focal adhesion complex, playing a role in mediating cell–cell adhesion and cytoskeletal dynamics. Moreover, zyxin shuttles between the cytoplasm and the nucleus, where it contributes to regulating gene expression. Although identified over 30 years ago, zyxin’s nuclear functions, particularly in relation to cancer, remain largely unexplored. In this study, we profiled zyxin binding to chromosomal DNA using metastatic prostate carcinoma PC3M cells as a model. Our ChIP-Seq results revealed that zyxin binds to chromosomal DNA, with mitochondrial pseudogenes as the primary targets. Furthermore, we demonstrated that the LIM domains of zyxin are sufficient for DNA binding and that zyxin knockdown leads to transcriptional changes in mitochondrial pseudogenes. Additionally, zyxin knockdown impacted several other genes associated with mitochondrial integrity and apoptosis, resulting in disturbances in MTCO2P2 RNA localization, mitochondrial membrane potential, increased reactive oxygen species, alterations in the cell cycle, and progression towards apoptosis. Overall, our work shows that zyxin directly interacts with nuclear DNA and regulates the transcription of mitochondrial pseudogenes, emphasizing its role in modulating mitochondrial function.
- 1 January 2025
- Published by Canadian Science Publishing in Biochemistry and Cell Biology
- Vol. 103, 1-16
Open AccessZyxin directly binds to chromosomal DNA and is linked with mitochondrial integrity and apoptosis
Human zyxin is a key component of the focal adhesion complex, playing a role in mediating cell–cell adhesion and cytoskeletal dynamics. Moreover, zyxin shuttles between the cytoplasm and the nucleus, where it contributes to regulating gene expression. Although identified over 30 years ago, zyxin’s nuclear functions, particularly in relation to cancer, remain largely unexplored. In this study, we profiled zyxin binding to chromosomal DNA using metastatic prostate carcinoma PC3M cells as a model. Our ChIP-Seq results revealed that zyxin binds to chromosomal DNA, with mitochondrial pseudogenes as the primary targets. Furthermore, we demonstrated that the LIM domains of zyxin are sufficient for DNA binding and that zyxin knockdown leads to transcriptional changes in mitochondrial pseudogenes. Additionally, zyxin knockdown impacted several other genes associated with mitochondrial integrity and apoptosis, resulting in disturbances in MTCO2P2 RNA localization, mitochondrial membrane potential, increased reactive oxygen species, alterations in the cell cycle, and progression towards apoptosis. Overall, our work shows that zyxin directly interacts with nuclear DNA and regulates the transcription of mitochondrial pseudogenes, emphasizing its role in modulating mitochondrial function.
- Top Cited PapersOpen Access
- 29 April 2024
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 44 (5)
Chloride ions in health and disease
Chloride is a key anion involved in cellular physiology by regulating its homeostasis and rheostatic processes. Changes in cellular Cl− concentration result in differential regulation of cellular functions such as transcription and translation, post-translation modifications, cell cycle and proliferation, cell volume, and pH levels. In intracellular compartments, Cl− modulates the function of lysosomes, mitochondria, endosomes, phagosomes, the nucleus, and the endoplasmic reticulum. In extracellular fluid (ECF), Cl− is present in blood/plasma and interstitial fluid compartments. A reduction in Cl− levels in ECF can result in cell volume contraction. Cl− is the key physiological anion and is a principal compensatory ion for the movement of the major cations such as Na+, K+, and Ca2+. Over the past 25 years, we have increased our understanding of cellular signaling mediated by Cl−, which has helped in understanding the molecular and metabolic changes observed in pathologies with altered Cl− levels. Here, we review the concentration of Cl− in various organs and cellular compartments, ion channels responsible for its transportation, and recent information on its physiological roles.
- 29 April 2024
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 44 (5)
Top Cited PapersOpen AccessChloride ions in health and disease
Chloride is a key anion involved in cellular physiology by regulating its homeostasis and rheostatic processes. Changes in cellular Cl− concentration result in differential regulation of cellular functions such as transcription and translation, post-translation modifications, cell cycle and proliferation, cell volume, and pH levels. In intracellular compartments, Cl− modulates the function of lysosomes, mitochondria, endosomes, phagosomes, the nucleus, and the endoplasmic reticulum. In extracellular fluid (ECF), Cl− is present in blood/plasma and interstitial fluid compartments. A reduction in Cl− levels in ECF can result in cell volume contraction. Cl− is the key physiological anion and is a principal compensatory ion for the movement of the major cations such as Na+, K+, and Ca2+. Over the past 25 years, we have increased our understanding of cellular signaling mediated by Cl−, which has helped in understanding the molecular and metabolic changes observed in pathologies with altered Cl− levels. Here, we review the concentration of Cl− in various organs and cellular compartments, ion channels responsible for its transportation, and recent information on its physiological roles.
- Open Access
- 12 October 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (11) , 105349
Biophysical characterization of chloride intracellular channel 6 (CLIC6)
- 12 October 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (11) , 105349
Open AccessBiophysical characterization of chloride intracellular channel 6 (CLIC6)
- Open Access
- 21 October 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (42) , eabo1244
CLIC4 localizes to mitochondrial-associated membranes and mediates cardioprotection
Mitochondrial-associated membranes (MAMs) are known to modulate organellar and cellular functions and can subsequently affect pathophysiology including myocardial ischemia-reperfusion (IR) injury. Thus, identifying molecular targets in MAMs that regulate the outcome of IR injury will hold a key to efficient therapeutics. Here, we found chloride intracellular channel protein (CLIC4) presence in MAMs of cardiomyocytes and demonstrate its role in modulating ER and mitochondrial calcium homeostasis under physiological and pathological conditions. In a murine model, loss of CLIC4 increased myocardial infarction and substantially reduced cardiac function after IR injury. CLIC4 null cardiomyocytes showed increased apoptosis and mitochondrial dysfunction upon hypoxia-reoxygenation injury in comparison to wild-type cardiomyocytes. Overall, our results indicate that MAM-CLIC4 is a key mediator of cellular response to IR injury and therefore may have a potential implication on other pathophysiological processes.
- 21 October 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (42) , eabo1244
Open AccessCLIC4 localizes to mitochondrial-associated membranes and mediates cardioprotection
Mitochondrial-associated membranes (MAMs) are known to modulate organellar and cellular functions and can subsequently affect pathophysiology including myocardial ischemia-reperfusion (IR) injury. Thus, identifying molecular targets in MAMs that regulate the outcome of IR injury will hold a key to efficient therapeutics. Here, we found chloride intracellular channel protein (CLIC4) presence in MAMs of cardiomyocytes and demonstrate its role in modulating ER and mitochondrial calcium homeostasis under physiological and pathological conditions. In a murine model, loss of CLIC4 increased myocardial infarction and substantially reduced cardiac function after IR injury. CLIC4 null cardiomyocytes showed increased apoptosis and mitochondrial dysfunction upon hypoxia-reoxygenation injury in comparison to wild-type cardiomyocytes. Overall, our results indicate that MAM-CLIC4 is a key mediator of cellular response to IR injury and therefore may have a potential implication on other pathophysiological processes.
- Open Access
- 29 October 2021
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 5 (10) , 884-897
PRMT5 Promotes Symmetric Dimethylation of RNA Processing Proteins and Modulates Activated T Cell Alternative Splicing and Ca2+/NFAT Signaling
Protein arginine methyltransferase (PRMT) 5 is the type 2 methyltransferase catalyzing symmetric dimethylation of arginine. PRMT5 inhibition or deletion in CD4 Th cells reduces TCR engagement-induced IL-2 production and Th cell expansion and confers protection against experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis. However, the mechanisms by which PRMT5 modulates Th cell proliferation are still not completely understood, and neither are the methylation targets in T cells. In this manuscript, we uncover the role of PRMT5 on alternative splicing in activated mouse T cells and identify several targets of PRMT5 symmetric dimethylation involved in splicing. In addition, we find a possible link between PRMT5-mediated alternative splicing of transient receptor potential cation channel subfamily M member 4 (Trpm4) and TCR/NFAT signaling/IL-2 production. This understanding may guide development of drugs targeting these processes to benefit patients with T cell–mediated diseases.
- 29 October 2021
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 5 (10) , 884-897
Open AccessPRMT5 Promotes Symmetric Dimethylation of RNA Processing Proteins and Modulates Activated T Cell Alternative Splicing and Ca2+/NFAT Signaling
Protein arginine methyltransferase (PRMT) 5 is the type 2 methyltransferase catalyzing symmetric dimethylation of arginine. PRMT5 inhibition or deletion in CD4 Th cells reduces TCR engagement-induced IL-2 production and Th cell expansion and confers protection against experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis. However, the mechanisms by which PRMT5 modulates Th cell proliferation are still not completely understood, and neither are the methylation targets in T cells. In this manuscript, we uncover the role of PRMT5 on alternative splicing in activated mouse T cells and identify several targets of PRMT5 symmetric dimethylation involved in splicing. In addition, we find a possible link between PRMT5-mediated alternative splicing of transient receptor potential cation channel subfamily M member 4 (Trpm4) and TCR/NFAT signaling/IL-2 production. This understanding may guide development of drugs targeting these processes to benefit patients with T cell–mediated diseases.
- Open Access
- 18 August 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (8) , 1299
Tumor-Induced Cardiac Dysfunction: A Potential Role of ROS
Cancer and heart diseases are the two leading causes of mortality and morbidity worldwide. Many cancer patients undergo heart-related complications resulting in high incidences of mortality. It is generally hypothesized that cardiac dysfunction in cancer patients occurs due to cardiotoxicity induced by therapeutic agents, used to treat cancers and/or cancer-induced cachexia. However, it is not known if localized tumors or unregulated cell growth systemically affect heart function before treatment, and/or prior to the onset of cachexia, hence, making the heart vulnerable to structural or functional abnormalities in later stages of the disease. We incorporated complementary mouse and Drosophila models to establish if tumor induction indeed causes cardiac defects even before intervention with chemotherapy or onset of cachexia. We focused on one of the key pathways involved in irregular cell growth, the Hippo–Yorkie (Yki), pathway. We used overexpression of the transcriptional co-activator of the Yki signaling pathway to induce cellular overgrowth, and show that Yki overexpression in the eye tissue of Drosophila results in compromised cardiac function. We rescue these cardiac phenotypes using antioxidant treatment, with which we conclude that the Yki induced tumorigenesis causes a systemic increase in ROS affecting cardiac function. Our results show that systemic cardiac dysfunction occurs due to abnormal cellular overgrowth or cancer elsewhere in the body; identification of specific cardiac defects associated with oncogenic pathways can facilitate the possible early diagnosis of cardiac dysfunction.
- 18 August 2021
- Published by MDPI AG in Antioxidants
- Vol. 10 (8) , 1299
Open AccessTumor-Induced Cardiac Dysfunction: A Potential Role of ROS
Cancer and heart diseases are the two leading causes of mortality and morbidity worldwide. Many cancer patients undergo heart-related complications resulting in high incidences of mortality. It is generally hypothesized that cardiac dysfunction in cancer patients occurs due to cardiotoxicity induced by therapeutic agents, used to treat cancers and/or cancer-induced cachexia. However, it is not known if localized tumors or unregulated cell growth systemically affect heart function before treatment, and/or prior to the onset of cachexia, hence, making the heart vulnerable to structural or functional abnormalities in later stages of the disease. We incorporated complementary mouse and Drosophila models to establish if tumor induction indeed causes cardiac defects even before intervention with chemotherapy or onset of cachexia. We focused on one of the key pathways involved in irregular cell growth, the Hippo–Yorkie (Yki), pathway. We used overexpression of the transcriptional co-activator of the Yki signaling pathway to induce cellular overgrowth, and show that Yki overexpression in the eye tissue of Drosophila results in compromised cardiac function. We rescue these cardiac phenotypes using antioxidant treatment, with which we conclude that the Yki induced tumorigenesis causes a systemic increase in ROS affecting cardiac function. Our results show that systemic cardiac dysfunction occurs due to abnormal cellular overgrowth or cancer elsewhere in the body; identification of specific cardiac defects associated with oncogenic pathways can facilitate the possible early diagnosis of cardiac dysfunction.
- 16 June 2020
- Published by Bentham Science Publishers Ltd. in The Natural Products Journal
- Vol. 10 (3) , 333-339
Cuminum cyminum Prevents Lipotoxicity and Apoptosis but Cuminaldehyde Fails to Do So: A Study on Mouse Macrophage (RAW 264.7) Cells
Aim: The present study aims to compare the cytoprotective effect of Cuminum cyminum L. (CC) extract and cuminaldehyde (CA) against lipotoxicity induced by oxidized low density lipoprotein (Ox-LDL) in mouse macrophage (RAW 264.7) cells.Objective: To assess comparative Cytoprotective potential of CC and CA against Ox-LDL induced cytotoxicity. ii) To study efficacy of CC and CA in preventing Ox-LDL induced apoptosisMethods: Protective effect of CC extract and CA aganist Ox-LDL induced cytotoxicity in RAW 264.7 cells was assessed by MTT assay. DCFDA stain was used to check the generation of ROS followed by analysis of apoptotic genes by quantitative RT-PCR.Results: CC extract was found to be non-toxic up to 300 μg/ml but CA showed significant toxicity from 50 to 300 μg/ml. Cells treated with Ox-LDL recorded 80 % decrement in cell viability as compared to the control cells. But Ox-LDL+CC treated group accounted for improved cell viability (88 %) which was comparable to that of control. However, Ox-LDL+CA treated cells did not record any improvement in cell viability (19 %). DCF-DA staining revealed that the presence of CC could minimize intracellular oxidative stress but similarly this was persistent in CA supplemented group. Furthermore, mRNA expression of apoptotic genes revealed that Ox-LDL induced upregulation of Bax and downregulation of Bcl-2 genes were not recorded in Ox-LDL+CC treated group.Conclusion: It can be concluded that CC extract efficiently prevented Ox-LDL induced lipotoxicity and apoptosis and has an anti-atherosclerotic potential. The failure of CA emphasizes the importance of naturally occurring polyherbal formulations over pure compounds in imparting bioactivity and for therapeutic applications.
- 16 June 2020
- Published by Bentham Science Publishers Ltd. in The Natural Products Journal
- Vol. 10 (3) , 333-339
Cuminum cyminum Prevents Lipotoxicity and Apoptosis but Cuminaldehyde Fails to Do So: A Study on Mouse Macrophage (RAW 264.7) Cells
Aim: The present study aims to compare the cytoprotective effect of Cuminum cyminum L. (CC) extract and cuminaldehyde (CA) against lipotoxicity induced by oxidized low density lipoprotein (Ox-LDL) in mouse macrophage (RAW 264.7) cells.Objective: To assess comparative Cytoprotective potential of CC and CA against Ox-LDL induced cytotoxicity. ii) To study efficacy of CC and CA in preventing Ox-LDL induced apoptosisMethods: Protective effect of CC extract and CA aganist Ox-LDL induced cytotoxicity in RAW 264.7 cells was assessed by MTT assay. DCFDA stain was used to check the generation of ROS followed by analysis of apoptotic genes by quantitative RT-PCR.Results: CC extract was found to be non-toxic up to 300 μg/ml but CA showed significant toxicity from 50 to 300 μg/ml. Cells treated with Ox-LDL recorded 80 % decrement in cell viability as compared to the control cells. But Ox-LDL+CC treated group accounted for improved cell viability (88 %) which was comparable to that of control. However, Ox-LDL+CA treated cells did not record any improvement in cell viability (19 %). DCF-DA staining revealed that the presence of CC could minimize intracellular oxidative stress but similarly this was persistent in CA supplemented group. Furthermore, mRNA expression of apoptotic genes revealed that Ox-LDL induced upregulation of Bax and downregulation of Bcl-2 genes were not recorded in Ox-LDL+CC treated group.Conclusion: It can be concluded that CC extract efficiently prevented Ox-LDL induced lipotoxicity and apoptosis and has an anti-atherosclerotic potential. The failure of CA emphasizes the importance of naturally occurring polyherbal formulations over pure compounds in imparting bioactivity and for therapeutic applications.